EpochX: Building the Infrastructure for an Emergent Agent Civilization

General-purpose technologies reshape economies less by improving individual tools than by enabling new ways to organize production and coordination. We believe AI agents are approaching a similar inflection point: as foundation models make broad task execution and tool use increasingly accessible, the binding constraint shifts from raw capability to how work is delegated, verified, and rewarded at scale. We introduce EpochX, a credits-native marketplace infrastructure for human-agent production networks. EpochX treats humans and agents as peer participants who can post tasks or claim them. Claimed tasks can be decomposed into subtasks and executed through an explicit delivery workflow with verification and acceptance. Crucially, EpochX is designed so that each completed transaction can produce reusable ecosystem assets, including skills, workflows, execution traces, and distilled experience. These assets are stored with explicit dependency structure, enabling retrieval, composition, and cumulative improvement over time. EpochX also introduces a native credit mechanism to make participation economically viable under real compute costs. Credits lock task bounties, budget delegation, settle rewards upon acceptance, and compensate creators when verified assets are reused. By formalizing the end-to-end transaction model together with its asset and incentive layers, EpochX reframes agentic AI as an organizational design problem: building infrastructures where verifiable work leaves persistent, reusable artifacts, and where value flows support durable human-agent collaboration.

Predicting Neo-Adjuvant Chemotherapy Response in Triple-Negative Breast Cancer Using Pre-Treatment Histopathologic Images

Triple-negative breast cancer (TNBC) is an aggressive subtype defined by the lack of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression, resulting in limited targeted treatment options. Neoadjuvant chemotherapy (NACT) is the standard treatment for early-stage TNBC, with pathologic complete response (pCR) serving as a key prognostic marker; however, only 40-50% of patients with TNBC achieve pCR. Accurate prediction of NACT response is crucial to optimize therapy, avoid ineffective treatments, and improve patient outcomes. In this study, we developed a deep learning model to predict NACT response using pre-treatment hematoxylin and eosin (H&E)-stained biopsy images. Our model achieved promising results in five-fold cross-validation (accuracy: 82%, AUC: 0.86, F1-score: 0.84, sensitivity: 0.85, specificity: 0.81, precision: 0.80). Analysis of model attention maps in conjunction with multiplexed immunohistochemistry (mIHC) data revealed that regions of high predictive importance consistently colocalized with tumor areas showing elevated PD-L1 expression, CD8+ T-cell infiltration, and CD163+ macrophage density - all established biomarkers of treatment response. Our findings indicate that incorporating IHC-derived immune profiling data could substantially improve model interpretability and predictive performance. Furthermore, this approach may accelerate the discovery of novel histopathological biomarkers for NACT and advance the development of personalized treatment strategies for TNBC patients.